AmCad BioMed Corporation
AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company's products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, … Read more
AmCad BioMed Corporation (4188) - Total Assets
Latest total assets as of December 2025: $U622.70 Million UYU
Based on the latest financial reports, AmCad BioMed Corporation (4188) holds total assets worth $U622.70 Million UYU as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
AmCad BioMed Corporation - Total Assets Trend (2021–2025)
This chart illustrates how AmCad BioMed Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
AmCad BioMed Corporation - Asset Composition Analysis
Current Asset Composition (December 2025)
AmCad BioMed Corporation's total assets of $U622.70 Million consist of 65.8% current assets and 34.2% non-current assets.
| Asset Category | Amount (UYU) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $U0.00 | 4.0% |
| Accounts Receivable | $U9.34 Million | 1.5% |
| Inventory | $U27.34 Million | 4.4% |
| Property, Plant & Equipment | $U0.00 | 0.0% |
| Intangible Assets | $U59.94 Million | 9.6% |
| Goodwill | $U0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how AmCad BioMed Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AmCad BioMed Corporation's current assets represent 65.8% of total assets in 2025, an increase from 65.1% in 2021.
- Cash Position: Cash and equivalents constituted 4.0% of total assets in 2025, down from 9.5% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 9.6% of total assets.
AmCad BioMed Corporation Competitors by Total Assets
Key competitors of AmCad BioMed Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
AmCad BioMed Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - AmCad BioMed Corporation generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - AmCad BioMed Corporation is currently not profitable relative to its asset base.
AmCad BioMed Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 22.62 | 16.63 | 21.24 |
| Quick Ratio | 21.11 | 15.43 | 20.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $U391.87 Million | $U 392.94 Million | $U 487.88 Million |
AmCad BioMed Corporation - Advanced Valuation Insights
This section examines the relationship between AmCad BioMed Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.58 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -10.4% |
| Total Assets | $U622.70 Million |
| Market Capitalization | $9.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values AmCad BioMed Corporation's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: AmCad BioMed Corporation's assets decreased by 10.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for AmCad BioMed Corporation (2021–2025)
The table below shows the annual total assets of AmCad BioMed Corporation from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $U622.70 Million | -10.39% |
| 2024-12-31 | $U694.87 Million | +35.55% |
| 2023-12-31 | $U512.65 Million | -7.44% |
| 2022-12-31 | $U553.86 Million | -10.05% |
| 2021-12-31 | $U615.75 Million | -- |